NCT06989112 · Interventional trial
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Overall registry status Recruiting
Phase 3
Conditions Endometrial Cancer
Delaware Valley sites
- Research Site · Abington, PA · Montgomery County · Withdrawn
- Research Site · Philadelphia, PA · Philadelphia County · Recruiting
First posted
Registry updated
Added to the directory